Longeveron (LGVN) Gains from Sales and Divestitures (2022 - 2026)
Longeveron (LGVN) recorded quarterly Gains from Sales and Divestitures of $332514.0 in Q1 2026, down 49.31% quarter-over-quarter from $655922.0 in Q4 2025, and up 236.69% on a YoY basis from $98761.0 in Q1 2025.
Longeveron (LGVN) Gains from Sales and Divestitures (2022 - 2026) Analysis & Trends
Longeveron's Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $332514.0 for Q1 2026.
- In Q1 2026, Gains from Sales and Divestitures rose 236.69% year-over-year to $332514.0; the TTM figure through Mar 2026 stood at $332514.0 (up 236.69% YoY), while the FY2025 annual figure was $655922.0, up 15.7% from the prior year.
- Gains from Sales and Divestitures was $332514.0 for Q1 2026 at Longeveron, down from $655922.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $655922.0 in Q4 2025 to a low of $3306.0 in Q1 2024.
- Historically, Gains from Sales and Divestitures has averaged $308347.6 across 5 years, with a median of $332514.0 in 2026.
- Biggest YoY gain for Gains from Sales and Divestitures was 4069.74% in 2025; the steepest drop was 3.43% in 2025.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $152117.0 in 2022, then soared by 74.59% to $265584.0 in 2023, then soared by 113.46% to $566904.0 in 2024, then climbed by 15.7% to $655922.0 in 2025, then slumped by 49.31% to $332514.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $332514.0 (Q1 2026), $655922.0 (Q4 2025), and $469328.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 332,514.00 |
| Mar 31, 2026 | 332,514.00 |
| Dec 31, 2025 | 655,922.00 |
| Dec 31, 2025 | 655,922.00 |
| Sep 30, 2025 | 469,328.00 |
| Sep 30, 2025 | 469,328.00 |
| Jun 30, 2025 | 352,927.00 |
| Jun 30, 2025 | 352,927.00 |
| Mar 31, 2025 | 98,761.00 |
| Mar 31, 2025 | 98,761.00 |
| Dec 31, 2024 | 566,904.00 |
| Dec 31, 2024 | 566,904.00 |
| Sep 30, 2024 | 485,997.00 |
| Sep 30, 2024 | 485,997.00 |
| Jun 30, 2024 | 8,464.00 |
| Jun 30, 2024 | 8,464.00 |
| Mar 31, 2024 | 3,306.00 |
| Mar 31, 2024 | 3,306.00 |
| Dec 31, 2023 | 265,584.00 |
| Dec 31, 2023 | 265,584.00 |